While radical cystectomy (RC) with pelvic lymph node dissection (PLND) represents the accepted gold standard for the treatment of muscle-invasive bladder cancer, this treatment approach is associated with significant morbidity. As such, bladder preservation strategies are often utilized in patients who are either deemed medically unfit due to significant comorbidities or whom decline management with RC and PLND secondary to its associated morbidity. In a select group of patients, meeting strict criteria, bladder preservation approaches may be employed with curative intent. Trimodal therapy, consisting of complete transurethral resection of bladder tumor (TURBT), chemotherapy, and radiation therapy has demonstrated durable oncologic control and long-term survival in a number of studies. The review presented here provides a description of trimodal therapy and the role of TURBT in bladder preservation for patients with muscle-invasive bladder cancer.
Bladder cancer (Amsterdam, Netherlands). 2016 Oct 27*** epublish ***
Christopher M Russell, Amir H Lebastchi, Tudor Borza, Daniel E Spratt, Todd M Morgan
Department of Urology, University of Michigan , Ann Arbor, MI, USA., Department of Radiation Oncology, University of Michigan , Ann Arbor, MI, USA.